[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seoul National University Bundang Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":631},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,48,74,100,132,156,174,193,212,235,259,281,301,324,350,375,397,423,445,468,499,532,557,583,610],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644754","remimazolam-on-the-incidence-of-postoperative-acute-kidney-injury-100644754",false,"NCT07674719","Remimazolam on the Incidence of Postoperative Acute Kidney Injury","The Effect of Intraoperative Remimazolam Administration on the Incidence of Postoperative Acute Kidney Injury After Hepatobiliary and Pancreatic Surgery : a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Ages 19 or older and under 85\n* Patients scheduled to undergo elective hepatopancreatic surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) physical grade 1-3\n* Those who voluntarily consented to a written informed consent form prior to participation in the study\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to other benzodiazepine drugs, including remimazolam, and to the components of this drug (e.g., patients with severe hypersensitivity to dextran 40)\n* Patients with hypersensitivity to propofol\n* Patients with underlying conditions: liver, neurological disorders, or acute narrow-angle glaucoma\n* Patients with severe or acute respiratory failure\n* Patients in shock or a coma\n* Patients taking TCA antidepressants\n* Patients with preoperative chronic kidney disease","ALL","19 Years","85 Years",{"count":21,"type":22},78,"ESTIMATED","INTERVENTIONAL",[25],"NA","We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.",[28,29,30,31,32,33,34],"Remimazolam","Propofol","Acute Kidney Injury","Hemodynamic Stability","Hepatobiliary Surgery","Fluid Therapy","Fluid Therapy DURING SURGERY","NOT_YET_RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":22},"2026-06-26",{"date":43,"type":22},"2028-06-26",{"name":45,"class":46},"Seoul National University Bundang Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100479659","kpmng-study-of-molecular-profiling-guided-therapy-based-on-genomic-alterations-in-advanced-solid-tumors-ii-100479659","NCT05525858","KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","KOrean Precision Medicine Networking Group Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","KOSMOSII","Inclusion Criteria:\n\n* 19 years of age or older\n* Histologically proven locally advanced or metastatic solid tumors\\*\\*\\* who showed disease progression on standard first line anti-cancer treatment and\u002For has no standard treatment option\n\n  \\*\\*\\* very rare diseases without standard treatment option which form solid mass, such as Erdheim Chester disease can be enrolled after KOSMOS MTB approval\n* A genomic test results must be available in a MFDS-accredited for laboratories offering service, or in part of clinical trial\u002Fstudy or other commercial labs approved and certified by regulatory bodies compatible with MFDS, such as CLIA. A genomic test can be conducted with tumor tissue as well as plasma circulating tumor DNA.\n\n  1. Results from genomic profiling tests performed after diagnosis with metastatic\u002Fadvanced disease to registration are acceptable. NGS results performed within three years prior to registration are preferred. Those patients with NGS results from primary tumor or more than 3 years prior to enrollment can be registered and whether NGS data is acceptable will be subject to MTB decision.\n  2. NGS panels should be i. Tested in a lab that is accredited by one or more quality assurance program (e.g., Korean Institute of Genomic Testing Evaluation, The Korean Society of Pathologists, Korean Society for Laboratory Medicine, Korea Laboratory Accreditation Scheme, etc.) ii. Patients who have insufficient genomic information from their NGS results (e.g., lack of variant calling format file or uninterpretable reports) or who are candidates of immunotherapy will submit their tissue and\u002For blood, for central NGS testing and exploratory biomarker analysis.\n* Ability to understand and the willingness to sign a written informed consent document\n* Life expectancy of at least 12 weeks\n* Adequate recovery from most recent systemic or local treatment for cancer.\n\nExclusion Criteria:\n\n* Patients receiving any anti-cancer treatment (local treatment, chemotherapy, immunotherapy, targeted therapy) within 2 weeks prior to the start of study treatment\n* Any clinical condition, according to the opinion of site physicians, which makes molecular profiling guided therapy not at the best interest of the participating patient.\n* Patients who have ongoing toxicities of ≥ CTCAE 2, other than peripheral neuropathy, related to previous anti-cancer treatment. Patients with ongoing peripheral neuropathy of ≥ CTCAE 3 will be excluded. Laboratory abnormalities ≥ CTCAE 2 considered as not clinically significant by the study physician will be allowed.\n* Pregnant or breastfeeding, or intending to become pregnant during the study",{"count":57,"type":22},1000,"OBSERVATIONAL","A national, prospective, multi-center, open-label, multi-cohort study comprised of a framework to screen patients for actionable targets and evaluation of molecular profiling guided therapy recommended by MTB based on genomic alterations using targeted and\u002For immunotherapies outside of the approved indications via local clinical practice (Tier 1 \\& 2) and clinical trials (Tier 3)",[61,62,63],"Solid Tumor","Advanced Solid Tumor","Metastatic Cancer","RECRUITING","2026-06-17",{"date":67,"type":39},"2026-06-22",{"date":69,"type":39},"2022-09-28",{"date":71,"type":22},"2027-03",{"name":45,"class":46},32,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100597749","phase-2-mfolfoxmfolfiri-vs-mfolfox-in-advanced-or-recurrent-biliary-tract-cancer-second-line-100597749","NCT07062536","mFOLFOX\u002FmFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","A Randomized Phase II Clinical Trial to Evaluate the Efficacy Alternating mFOLFOX\u002FmFOLFIRI Chemotherapy Regimen as a Second-line Treatment for Advanced Biliary Tract Cancer","Inclusion criteria (All eligibility criteria must be fulfilled)\n\n1. Age ≥ 19 years.\n2. Diagnosed with biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer.\n3. Either unresectable advanced disease or recurrence after curative surgery.\n4. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2\n5. First-Line Treatment Failure: Disease progression after at least one cycle of gemcitabine\u002Fcisplatin-based therapy or discontinuation of therapy due to adverse effects.\n6. Presence of evaluable or measurable lesions according to RECIST v1.1 criteria.\n7. Laboratory Criteria: optima bone marrow, liver, and kidney function within one week prior to enrollment: A. Hemoglobin \\> 9.0 g\u002FdL B. Absolute neutrophil count (ANC) \\> 1,000\u002FuL C. Platelet count \\> 75,000\u002FuL D. Serum creatinine \\< 1.5× upper limit of normal (ULN) E. AST\u002FALT \\< 3× ULN F. Total bilirubin \\< 1.5× ULN (biliary drainage is allowed).\n8. Patients who understand the study protocol, can provide written informed consent, and are aware of their right to withdraw at any time without penalty.\n9. Effective Contraception (for patients of childbearing potential receiving oxaliplatin):\n\nA. Male patients:\n\nMust use effective contraception during the study and for 12 months after treatment completion.\n\nB. Female patients:\n\nMust use effective contraception during the study and for 15 months after treatment completion.\n\n\\*Exclusion Criteria (Patients meeting any of the following criteria will be excluded from the study.)\n\n1. Patients with prior exposure to oxaliplatin or irinotecan in previous cancer treatments.\n2. Patients with metastatic or unresectable biliary tract cancer who have received second- line or higher chemotherapy.\n3. Pregnant or breastfeeding women.\n4. Patients with a history of other malignancies within the past 3 years, except for papillary or follicular thyroid cancer.\n5. Patients with uncontrolled infections or other systemic diseases.\n6. Patients with a history of myocardial infarction, unstable angina, or heart failure (NYHA\n7. Class III-IV) within the last 6 months.\n8. Patients with Grade 3 or higher peripheral neuropathy caused by prior chemotherapy.\n9. Patients with known allergic reactions to the investigational drugs.\n10. Known patients with Gilbert's syndrome, DPD (dihydro-pyrimidine dehydrogenase) deficiency, or Homozygous UGT1A1\\*28 alleles.\n11. Patients currently taking potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin), or potent CYP3A4 inducers (e.g., rifampin, carbamazepine, St.\n\n    John's Wort).\n12. Patients who are eligible for targeted therapy, including FGFR inhibitors or IDH1 inhibitors. (eligible for patient who unable to use these targeted agents due to drug cost.)\n13. Patients with active CNS metastases and\u002For carcinomatous meningitis.\n14. Patients who meet contraindications for the investigational drugs as per domestic regulatory guidelines, including patients with infections, Interstitial pneumonitis or pulmonary fibrosis, Severe diarrhea, Chronic inflammatory bowel disease, Intestinal paralysis or obstruction, Functional impairment due to peripheral sensory neuropathy, Severe renal dysfunction.\n15. Patients deemed ineligible by the investigator for any other reason.","99 Years",{"count":83,"type":22},130,[85],"PHASE2","In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX\u002FFOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.",[88],"Biliary Cancer Metastatic",[90,91],"second line","alternating mFOLFOX\u002FmFOLFIRI chemotherapy regimen","2026-05-27",{"date":94,"type":39},"2026-05-28",{"date":96,"type":22},"2026-06-01",{"date":98,"type":22},"2028-04-01",{"name":45,"class":46},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":47},"100639774","exploratory-trial-of-the-hidongdong-language-rehabilitation-app-for-articulation-delay-100639774","NCT07613268","Exploratory Trial of the \"HiDongDong\" Language Rehabilitation App for Articulation Delay.","A Prospective, Single-center, Randomized Controlled, Open-Label, Assessor-Blinded, Investigator-Initiated Exploratory Clinical Trial of the Application-Based Language Rehabilitation Program \"HiDongDong\" for Improving Language Development in Children Suspected of Articulation and Phonological Delay","Inclusion Criteria:\n\n1. Children aged 2 years to under 14 years\n2. Persistent difficulties in speech sound production, or reduced speech intelligibility that interferes with communicative participation, resulting in limitations in social participation, academic performance, or daily activities\n3. Articulation developmental delay suspected based on U-TAP results, with articulation performance more than 1 standard deviation below the mean for the same age group (-1SD)\n4. Sufficient cognitive ability to follow simple instructions via a mobile device (tablet)\n5. For children under 7 years of age: a caregiver who has received sufficient explanation of the study purpose and procedures and has voluntarily provided written informed consent\n6. For children aged 7 years or older: voluntary assent from the child after sufficient explanation of the study purpose and procedures by the investigator,\n\nin addition to written informed consent from the caregiver\n\nExclusion Criteria:\n\n1. Caregiver or child does not consent to study participation, or withdraws consent during the study\n2. U-TAP results indicate articulation development within the normal range, with no suspicion of articulation developmental delay\n3. Difficulty understanding simple instructions or participating in assessments and training due to moderate or severe cognitive impairment, attention deficit, autism spectrum disorder, or similar conditions\n4. Significantly limited speech production due to neuromuscular or anatomical causes, including severe visual impairment or visual field deficits, hearing impairment, cleft palate structural abnormalities, or severe oral\u002Ffacial muscle dysfunction, resulting in difficulty with articulation\n5. Inability to continue study participation due to acute illness or other conditions that may affect assessment or training during the study period, or unwillingness of the caregiver or child to continue participation\n6. Determination by the principal investigator that study participation may pose a risk to the safety or well-being of the child\n\nAny one of the above exclusion criteria is sufficient for exclusion.","2 Years","13 Years",{"count":110,"type":22},48,[25],"The purpose of this study is to evaluate the effectiveness of the AI-based application \"HiDongDong\" in improving articulation development in children aged 2 to under 14 years with suspected articulation delays. The program provides individualized language training based on a personalized assessment of vulnerable speech sounds. This trial aims to determine whether the digital therapeutic solution can enhance articulation skills and inform future strategies for language rehabilitation in children.",[114,115,116],"Speech Sound Disorder","Language Development Disorders","Phonological Disorder",[118,119,120,121,122,123,114,115],"Phonological Delay","AI-based Therapy","Digital Therapeutic","Pediatric Speech Development","Application-Based Language Rehabilitation","Articulation Delay","2026-05-26",{"date":126,"type":39},"2026-05-29",{"date":128,"type":22},"2026-05",{"date":130,"type":22},"2026-08",{"name":45,"class":46},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":47},"100546813","phase-4-enavogliflozin-vs-pioglitazone-on-glucose-and-atherosclerosis-100546813","NCT06399835","Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis","Comparing Enavogliflozin and Pioglitazone as Add-ons to Metformin With\u002FWithout Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes","Inclusion Criteria:\n\n* Type 2 diabetes patients with a glycated hemoglobin (HbA1c) level of 7.0 - 10.5% at screening\n* Males or females aged 20-80 years\n* Individuals who have been taking Metformin (≥ 500mg) with or without a DPP-4 inhibitor (such as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin) for at least the past 3 months\n* Body mass index ≥ 23 kg\u002Fm²\n* Estimated glomerular filtration ratio (eGFR) ≥ 60 ml\u002Fmin\u002F1.73m²\n\nExclusion Criteria:\n\n* Patients with Type 1 Diabetes, Gestational Diabetes, or secondary diabetes due to other causes\n* Patients with a history of acute cardiovascular disease within the last 3 months prior to the screening visit\n* Pregnant or breastfeeding patients, or patients not using contraception. Patients with chronic Hepatitis B or C (excluding healthy carriers of Hepatitis B), or liver disease (aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) \\> 3 times the upper limit of normal)\n* Patients with heart failure or a history of heart failure\n* Individuals with a history of cancer within the past 5 years (excluding those adequately treated for squamous cell carcinoma or thyroid cancer)\n* Patients who have participated in another clinical study within the last 30 days\n* Alcohol addiction\n* Patients for whom the use of Enavogliflozin or Pioglitazone is contraindicated\n* Patients taking other oral hypoglycemic agents or insulin or other investigational drugs\n* Patients deemed unsuitable for the study based on the investigator's judgment","20 Years","80 Years",{"count":142,"type":22},120,[144],"PHASE4","The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will compare changes in other metabolic or cardiovascular risk factors, such as triglycerides, high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory markers, between the two drugs.",[147],"Type 2 Diabetes","2026-05-02",{"date":150,"type":39},"2026-05-05",{"date":152,"type":39},"2024-02-01",{"date":154,"type":22},"2027-12-31",{"name":45,"class":46},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":47},"100547036","phase-4-clopidogrel-versus-cilostazol-on-vessels-100547036","NCT06402747","Clopidogrel Versus Cilostazol on Vessels","Comparing Clopidogrel and Cilostazol in Type 2 Diabetes Patients With Carotid Atherosclerosis","Inclusion Criteria:\n\n* Adults with diabetes aged 19 and older\n* Individuals with a carotid ultrasound cIMT (carotid intima-media thickness) of 1.0mm or more\n* Those who have not changed their combination therapy medications (including oral hypoglycemics, antihypertensives, and lipid-lowering drugs) in the last three months\n* Individuals with an HbA1c level of 10% or less\n* Those who have voluntarily signed the written consent form and agreed to participate in the study\n\nExclusion Criteria:\n\n* Individuals currently using antithrombotic or anticoagulant medications other than aspirin\n* Individuals with bleeding or conditions that may increase the risk of bleeding, such as:\n\n  * Hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal bleeding, urinary bleeding, hemoptysis, vitreous hemorrhage, etc\n  * Active peptic ulcer, hemorrhagic stroke within the last 6 months, surgical operations within the last 3 months, proliferative diabetic retinopathy, uncontrolled hypertension\n* Patients who have had cerebrovascular or cardiovascular complications within the past 6 months (including stroke, transient ischemic attacks, myocardial infarction, unstable angina, coronary artery bypass graft, or percutaneous coronary intervention)\n* Patients with severe renal or hepatic diseases\n* Patients with congestive heart failure\n* Individuals with a history of hypersensitivity to the drug or its components\n* Pregnant women or women who may be pregnant\n* Women who are breastfeeding or plan to breastfeed during the study",{"count":142,"type":22},[144],"Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance of atherosclerosis, is advancing. Due to lifestyle changes and an aging population, Koreans, especially diabetics, are developing more vascular diseases and are at higher risk for peripheral vascular disorders. Diabetics with lower limb peripheral artery disease require effective therapy to avoid major complications and a reduced quality of life. Although licensed for symptom control, Clopidogrel and Cilostazol have not yet been established for primary prevention of cardiovascular risks. These medications will be evaluated for their potential as primary preventive agents against cardiovascular disease in type 2 diabetes patients. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and to evaluate their influence on hemorheological changes in individuals with Type 2 diabetes. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and evaluating their influence on alterations in blood flow among individuals with Type 2 diabetes.",[147,167],"Atherosclerosis",{"date":150,"type":39},{"date":170,"type":39},"2024-04-16",{"date":172,"type":22},"2027-01-31",{"name":45,"class":46},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":192,"locationsCount":47},"100467335","phase-4-choline-fenofibrate-and-carotid-atherosclerosis-in-patients-with-type-2-diabetes-and-combined-dyslipidemia-100467335","NCT05365425","Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Choline Fenofibrate on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia: triglyceride 200\\~499 mg\u002FdL, HDL-cholesterol male ≤45 mg\u002FdL or female ≤50 mg\u002FdL\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension\n* Severe renal dysfunction\n* GOT\u002FGPT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)",{"count":182,"type":22},56,[144],"This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.",[186,167,187],"Dyslipidemia","Diabetes Mellitus, Type 2",{"date":150,"type":39},{"date":190,"type":39},"2023-06-01",{"date":154,"type":22},{"name":45,"class":46},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":140,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":47},"100467336","phase-4-atmeg-atorvastatin-and-omega-3-combination-and-carotid-atherosclerosis-in-patients-with-type-2-diabetes-and-combined-dyslipidemia-100467336","NCT05365438","Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia","Inclusion Criteria:\n\n* Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit\n* Male or female of 20 years or over\n* Mixed dyslipidemia under moderate-intensity statin: triglyceride ≥200 mg\u002FdL, HDL-cholesterol ≤50 mg\u002FdL, LDL-cholesterol ≥100 mg\u002FdL\n\n  * moderate-intensity statin: atorvastatin 10-20mg, rosuvastatin 5mg, simvastatin 20-40mg, pravastatin 40-80mg, lovastatin 40mg, fluvastatin XL 80mg, fluvastatin 40mg bid, pitavastatin 2-4mg\n* Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm\n* Asymptomatic patients without history of angina, myocardial infarction, or cerebral infarction\n* Creatinine ≤1.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Dyslipidemia which requires other therapy: triglyceride ≥500 mg\u002FdL or LDL-cholesterol ≥190 mg\u002FdL\n* Uncontrolled hypertension: SBP \\>180 mmHg or DBP \\>110 mmHg\n* Severe renal dysfunction: eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2\n* AST\u002FALT \\>120\u002F120 or chronic liver disease\n* Pregnant or childbearing woman who does not have enough contraception\n* Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months\n* Usage of dyslipidemia therapy other than statin",{"count":201,"type":22},105,[144],"This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.",[205,167,187],"Dyslipidemias",{"date":150,"type":39},{"date":208,"type":39},"2022-10-01",{"date":210,"type":22},"2026-12-31",{"name":45,"class":46},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":219,"sex":17,"minAge":220,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":47},"100545483","tegoprazan-containing-sequential-for-h-pylori-100545483","NCT06382493","Tegoprazan-containing Sequential for H. Pylori","Efficacy of Tegoprazan-containing Sequential Therapy Compared to Proton Pump Inhibitor-based Eradication in South Korea, a Region With High Antimicrobial Resistance: A Prospective Randomized Single Tertiary Center Study","Inclusion Criteria:\n\nPatients who had H. pylori infection proved by positive test result of urea breath test (UBT), rapid urase test or pathologic examination (warthin-giemsa staining)\n\nExclusion Criteria:\n\n* congestive heart failure, NYHA III or IV\n* end-stage renal disease\n* alcoholics\n* drug abusers\n* pregnant or nursing women",true,"18 Years",{"count":222,"type":22},400,[25],"As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy",[226],"Helicobacter Pylori Infection","2026-04-23",{"date":229,"type":39},"2026-04-28",{"date":231,"type":39},"2021-02-01",{"date":233,"type":22},"2026-12-12",{"name":45,"class":46},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":220,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":244,"conditions":245,"keywords":249,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":47},"100489430","predictors-of-prognosis-in-ibd-patients-100489430","NCT05653011","Predictors of Prognosis in IBD Patients","Predictors of Response After Induction Therapy With TNF-alpha Inhibitor in Inflammatory Bowel Disease, Comparison to Normal","Inclusion Criteria:\n\n* control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma)\n* TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment\n* TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor\n\nExclusion Criteria:\n\n* Age under 18 years\n* Patients who were treated with antibiotics or probiotics within the last 3 months",{"count":243,"type":22},100,"A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease",[246,247,248],"Inflammatory Bowel Diseases","Ulcerative Colitis","Crohn Disease",[250,251,252],"inflammatory bowel disease","ulcerative colitis","crohn's disease",{"date":254,"type":39},"2026-04-24",{"date":256,"type":39},"2013-03-11",{"date":210,"type":22},{"name":45,"class":46},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":220,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":267,"conditions":268,"keywords":271,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":47},"100467334","clinicopathological-characteristics-of-colon-cancer-in-young-age-100467334","NCT05365412","Clinicopathological Characteristics of Colon Cancer in Young Age","Inclusion Criteria:\n\n* Patients treated after being diagnosed with colorectal cancer\n\nExclusion Criteria:\n\n* Patients under age of 18 years, or patients who cannot choose whether to participate or not\n* Patients who refuse to participate in the study",{"count":266,"type":22},1400,"A Study on the Characteristics of Colorectal Cancer by Age and sex.",[269,270],"Colo-rectal Cancer","Molecular Pathway Deregulation",[272,273,274],"colorectal cancer","prognosis","sex difference",{"date":229,"type":39},{"date":277,"type":39},"2019-01-01",{"date":279,"type":22},"2026-12",{"name":45,"class":46},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":219,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":47},"100399536","clinical-trial-for-the-evaluation-of-the-efficacy-and-safety-of-edl-on-dyspepsia-100399536","NCT04482478","Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on Dyspepsia","A 12 Week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on Dyspepsia","Inclusion Criteria:\n\n1. Those over the age of 19\n2. Those diagnosed with functional dyspepsia (Rome IV\\*)\n\n   \\* One or more of the following symptoms are diagnosed when there is no organic cause in the test including the upper gastrointestinal endoscopy(if symptoms begin 6 months prior to Visit 1, and the symptoms are present in the past 3 months).\n   * Othersome postprandial fullness\n   * Unpleasant early satiation\n   * Unpleasant epigastric pain\n   * Unpleasant epigastric burning\n3. A person who has 4 or more of the 10 symptoms in the GIS (Gastrointestinal Symptom) questionnaire and has a total score of 12 or more (5-point Likert scale)\n4. When there is no organic disease in the gastroscopy performed at Visit 1 (however, it can be replaced by the test results within 3 months from Visit 1)\n5. A person who consented to participate in this clinical trial and signed a Informed consent form before the trail began.\n\nExclusion Criteria:\n\n1. Persons who are currently being treated with severe cardiovascular system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, nervous system, musculoskeletal system, mental, infectious diseases, and malignant tumors (however, considering the condition of the subjects, subjects can participate in the test according to investigator's judgment.)\n2. Persons with a history of peptic ulcer and reflux esophagitis within 6 months of Visit 1\n3. Those who have gastrointestinal surgery (except appendectomy and hemorrhoidectomy)\n4. Persons with a history of malignancy of the digestive system\n5. Those who have taken H2 receptor blockers, anticholinergic agents (muscarinic receptor antagonists), gastrin receptor antagonists, prostaglandin preparations, proton pump inhibitors, gastric mucosal protective agents, other drugs intended to treat gastritis, gastric health-related health functional food within 2 weeks of Visit 1\n6. Those who need to constantly take medications that can cause gastritis, such as adrenal cortical hormones, nonsteroidal anti-inflammatory drugs, and aspirin during the human application test {However, low-dose aspirin for cardiovascular disease prevention (100 mg\u002Fday or less) permit}\n7. In the Drinking Habit Questionnaire, those who had an average alcohol intake of 14 units or more for men and or more 7 units for women per week for the past month.\n8. Uncontrolled hypertension persons (systolic blood pressure of 160 mmHg or higher, or diastolic blood pressure of 100 mmHg or higher, measurement criteria after 10 minutes of stability in human subjects)\n9. Persons with uncontrolled diabetes (fasting blood sugar is over 180 mg\u002FdL)\n10. Those whose Creatinine is more than twice the normal upper limit of the study institution\n11. Those whose AST(GOT) or ALT(GPT) is more than 3 times the normal upper limit of the study institution\n12. Persons who are sensitive or allergic to investigational product for this clinical trial\n13. Pregnant, lactating or planning to become pregnant within 3 months\n14. Those who participated in other clinical trials within 3 months of Visit 1 or plan to participate in other clinical trials after the start of this clinical trials.\n15. A person who determines that the Investigator is inappropriate for clinical trials\n16. Employee of Department of Digestive Internal Medicine, Seoul National University Bundang Hospital",{"count":243,"type":22},[25],"This clinical trial was designed to evaluate the functional and safety effects on dyspeptic symptoms compared to the placebo when ingested with EDL (Extract of Dolichos lablab Linne) in adults who complain of dyspeptic symptoms.",[292],"Functional Dyspepsia",[292,294],"GSRS",{"date":229,"type":39},{"date":297,"type":39},"2020-07-01",{"date":299,"type":22},"2026-12-30",{"name":45,"class":46},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":219,"sex":17,"minAge":220,"maxAge":19,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":47},"100237761","the-efficacy-of-the-7-days-tailored-therapy-as-the-1st-eradication-of-h-pylori-infection-100237761","NCT02373280","The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori","Inclusion Criteria:\n\n* The patients who proved H. pylori infection following three methods\n\n  1. positive rapid urease test (CLOtest)\n  2. histologic evidence of H. pylori by modified Giemsa staining\n  3. positive Urea breath test\n* Male and female Korean Adult (Aged ≥ 18 years)\n\nExclusion Criteria:\n\n* Patients who received eradication therapy for H. pylori infection, previously\n* H. pylori eradication failure because of poor compliance\n* the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks\n* Advanced gastric cancer or other malignancy\n* Abnormal liver function or liver cirrhosis\n* Abnormal renal function or chronic kidney disease\n* Other severe concurrent diseases\n* Previous allergic reactions to the study drugs\n* Pregnant or lactating women",{"count":309,"type":22},600,[25],"To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.",[313],"Helicobacter Infection",[315,316,317],"Helicobacter pylori","tailored therapy","eradication",{"date":254,"type":39},{"date":320,"type":4},"2014-08",{"date":322,"type":22},"2027-12",{"name":45,"class":46},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":339,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":47},"100635292","contrast-induced-acute-kidney-injury-prevention-in-acute-heart-failure-100635292","NCT07550790","Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure","Contrast-Induced Acute Kidney Injury in Acute Heart Failure With Renal Dysfunction: The Kidney Protection Strategies Evaluation in Acute Heart Failure (K-PROSE)","K-PROSE","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Emergency department visit\u002Fhospitalization for acute heart failure with clinical evidence of congestion\n* Planned contrast-enhanced computed tomography during the index hospitalization\n* Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL\u002Fmin\u002F1.73 m²\n\nExclusion Criteria:\n\n* Requirement for vasopressor therapy\n* Requirement for renal replacement therapy (dialysis)\n* Known allergy or hypersensitivity to furosemide\n* Ongoing acute coronary syndrome\n* Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test\n* Hyperkalemia (serum potassium \\>5.5 mmol\u002FL)\n* Uncorrected volume depletion or hyponatremia (serum sodium \\\u003C130 mmol\u002FL)\n* Any condition deemed by the investigator to make participation in the study inappropriate",{"count":333,"type":22},190,[25],"The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL\u002Fmin\u002F1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.",[337,338],"Heart Failure Acute","Renal Dysfunction",[340,341,342],"contrast-induced acute kidney injury","decongestion","hydration","2026-04-19",{"date":254,"type":39},{"date":346,"type":22},"2026-05-01",{"date":348,"type":22},"2029-01-30",{"name":45,"class":46},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":359,"conditions":360,"keywords":364,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":374,"locationsCount":47},"100634453","effect-of-oxiris-hemofilter-use-in-septic-shock-a-multicenter-retrospective-cohort-study-100634453","NCT07539883","Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study","Official Title: Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study Using a Target Trial Emulation Approach","Inclusion Criteria:\n\n* Adults aged 19 years or older.\n* Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025.\n* Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI).\n\nExclusion Criteria:\n\n* Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission.\n* Patients with End-Stage Renal Disease (ESRD).\n* Patients with missing critical covariates.",{"count":358,"type":22},360,"This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.",[361,362,363],"Septic Shock","Multiorgan Failure","Sepsis",[365,366,367],"oXiris","Target Trial Emulation","Extracorporeal Blood Purification","2026-04-13",{"date":370,"type":39},"2026-04-20",{"date":372,"type":39},"2026-01-22",{"date":210,"type":22},{"name":45,"class":46},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":382,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":47},"100628588","cerebral-oxygen-consumption-response-to-increased-oxygen-supply-and-postoperative-delirium-in-older-surgical-patients-100628588","NCT07463586","Cerebral Oxygen Consumption Response to Increased Oxygen Supply and Postoperative Delirium in Older Surgical Patients","Association Between Cerebral Oxygen Consumption Responsiveness to Increased Oxygen Supply and Postoperative Delirium: A Prospective Observational Study Using Functional Near-Infrared Spectroscopy","Inclusion Criteria:\n\n* Patients undergoing elective laparoscopic surgery under general anesthesia\n* Age 65 years or older\n\nExclusion Criteria:\n\n* Diagnosis of dementia or presence of delirium before surgery\n* Loss of capacity to provide informed consent\n* Moderate or severe cerebrovascular stenosis diagnosed before surgery\n* Moderate or severe obstructive or restrictive pulmonary dysfunction identified on preoperative pulmonary function testing\n* Requirement for supplemental oxygen therapy before surgery\n* History of neurological disorders (e.g., Parkinson's disease, stroke) or prior brain surgery\n* Severe hepatic dysfunction (AST or ALT \\> 120 IU\u002FL)\n* Severe renal dysfunction (estimated GFR \\\u003C 15 mL\u002Fmin\u002F1.73 m²)\n* Persistent severe hemodynamic instability (mean arterial pressure \\\u003C 60 mmHg)\n* Skin conditions preventing placement of the forehead fNIRS sensor\n* Combined surgical procedures performed concurrently\n* Planned postoperative admission to the intensive care unit","65 Years",{"count":384,"type":22},80,"The goal of this observational study is to learn whether the brain's ability to use oxygen during surgery is associated with postoperative delirium in adults aged 65 years and older undergoing general anesthesia.\n\nThe main question it aims to answer is:\n\n\\- Does reduced cerebral oxygen consumption responsiveness during surgery increase the risk of postoperative delirium in older patients?\n\nParticipants who are undergoing elective laparoscopic surgery under general anesthesia as part of their routine medical care will have brain oxygen levels measured during surgery using a non-invasive forehead sensor, and will be assessed for delirium for up to three days after surgery.",[387,388],"Delirium - Postoperative","Cerebral Oxygenation","2026-03-29",{"date":391,"type":39},"2026-04-02",{"date":393,"type":39},"2026-03-11",{"date":395,"type":22},"2028-05",{"name":45,"class":46},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":219,"sex":17,"minAge":382,"maxAge":19,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":4},"100629661","muscle-specific-multimodal-ai-for-sarcopenia-diagnosis-100629661","NCT07477574","Muscle-Specific Multimodal AI for Sarcopenia Diagnosis","Development of Muscle-specific Multi-modal AI for Sarcopenia Diagnosis: Effects of Rehabilitation Training on Ant-muscle Aging","SARC-AI","Inclusion Criteria:\n\n* Adults aged 65 years or older\n* Individuals with reduced muscle function or at risk of sarcopenia\n* Able to participate in rehabilitation training\n* Able to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Severe cardiovascular, neurological, or musculoskeletal conditions that limit participation in exercise\n* Severe cognitive impairment\n* Participation in other clinical trials that may influence study outcomes\n* Any medical condition judged by the investigator to make participation unsafe",{"count":406,"type":22},75,[25],"This study aims to develop a muscle-specific multimodal artificial intelligence (AI) model for the diagnosis of sarcopenia and to investigate the effects of rehabilitation training on muscle aging. Clinical, functional, and imaging data will be collected from participants with muscle function decline. Multimodal data, including muscle function measurements and clinical assessments, will be integrated to develop and validate an AI-based diagnostic model for sarcopenia. In addition, the effects of rehabilitation training on muscle function and muscle aging-related outcomes will be evaluated. The results of this study are expected to contribute to the development of digital biomarkers and precision rehabilitation strategies for sarcopenia.",[410],"Sarcopenia",[410,412,413,414],"Muscle aging","Multimodal AI","Muscle function","2026-03-12",{"date":417,"type":39},"2026-03-17",{"date":419,"type":22},"2026-03-01",{"date":421,"type":22},"2028-02-28",{"name":45,"class":46},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":219,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":436,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":47},"100628841","effects-of-frequency-adjustment-in-functional-electrical-stimulation-on-genioglossus-muscle-activity-100628841","NCT07466888","Effects of Frequency Adjustment in Functional Electrical Stimulation on Genioglossus Muscle Activity","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* STOP questionnaire score ≥ 2\n* Able to read and write in Korean\n* Voluntarily provides written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Refusal to undergo study procedures or failure to provide informed consent\n* Cognitive impairment or psychiatric disorders that interfere with the ability to follow study instructions\n* Pregnant or breastfeeding women\n* Known allergy or hypersensitivity to electrical stimulation pads or related materials (e.g., silicone, polypropylene, polyethylene)\n* Skin conditions preventing application of electrical stimulation (e.g., hypersensitive skin)\n* Medical conditions considered unsuitable for participation by the investigator (e.g., epilepsy, malignant tumor, high fever, diabetes mellitus, use of anticoagulants, phlebitis, thrombophlebitis, hemophilia)\n* Infectious disease or local conditions at the stimulation site (e.g., inflammation, wounds, abscess, edema)\n* Known cardiac disease or presence of a cardiac pacemaker or implanted electrical stimulation device\n* History of surgery involving the submental area or upper airway region",{"count":430,"type":22},28,[25],"This single-group interventional study investigates the safety and physiologic effects of functional electrical stimulation (FES) applied to the tongue and submental muscles in adults at high risk for sleep apnea. Participants will receive five stimulation frequencies (15, 25, 35, 45, and 75 Hz) in randomized order during a single visit. Ultrasound and tongue pressure (IOPI) measurements, as well as subjective assessments of discomfort and perceived effects, will be conducted before, during, and after stimulation. The primary objective is to evaluate changes in muscle thickness, length, and tongue strength across different stimulation frequencies. Secondary objectives include assessing participant discomfort, safety, and subjective treatment effects.",[434,435],"Obstructive Sleep Apnea (OSA)","Snoring",[434,435,437],"FES","2026-03-08",{"date":415,"type":39},{"date":441,"type":39},"2026-01-06",{"date":443,"type":22},"2026-04",{"name":45,"class":46},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":452,"targetDuration":4,"studyType":23,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":4},"100628291","comparison-of-eeg-timed-vs-repetitive-robot-therapy-for-chronic-stroke-100628291","NCT07459725","Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke","Exploratory Comparison of Movement Observation\u002FImagery-Timed Robot Activation and Repetitive Robot Activation on Training Effects and Neurophysiological Responses in Chronic Stroke Patients","Inclusion Criteria:\n\n* Patients diagnosed with stroke.\n* Adults aged 19 to 85 years old at the time of screening.\n\nExclusion Criteria:\n\n* Patients with severe, uncontrolled medical conditions.\n* Patients with uncontrolled hypertension, diabetes mellitus, or renal disease.\n* Patients with severe cognitive impairment that prevents them from following instructions for motor tasks (Mini-Mental State Examination \\[MMSE\\] score of 15 or below).\n\nNote: Patients with an MMSE score of 15 or below may still be included if the Principal Investigator (or a delegated physician) determines that they have the capacity to perform the tasks and provide informed consent.",{"count":453,"type":22},20,[25],"This clinical trial compares two types of robotic hand rehabilitation-brain wave (EEG)-timed therapy versus simple repetitive therapy-to see which is more effective for recovering hand function in patients with chronic stroke. Participants will be randomly assigned to either group and will attend sessions using a wearable robotic hand device while wearing an EEG cap. In the EEG-timed group, the robot assists hand movements when participants successfully imagine moving and create specific brain signals, whereas in the repetitive group, the robot moves the hand automatically at set intervals. Both groups will receive a matched dose of robotic training to ensure a fair comparison of how the brain and hand function respond to the therapy.",[457,458,459],"Stroke","Chronic Stroke","Hemiparesis","2026-03-05",{"date":462,"type":39},"2026-03-10",{"date":464,"type":22},"2026-03-16",{"date":466,"type":22},"2028-12-31",{"name":45,"class":46},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":219,"sex":17,"minAge":107,"maxAge":474,"enrollmentInfo":475,"targetDuration":477,"studyType":58,"phases":4,"briefSummary":478,"conditions":479,"keywords":483,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":47},"100627949","surface-electromyographic-analysis-of-normal-swallowing-in-children-an-exploratory-study-100627949","NCT07455279","Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study","Inclusion Criteria:\n\n* Children aged 2 to under 10 years\n* Children without a diagnosis of dysphagia\n* Children without congenital brain lesions or respiratory conditions (e.g., bronchopulmonary dysplasia \\[BPD\\], respiratory distress syndrome \\[RDS\\]) that may affect the swallowing process\n* Children whose legal guardians provide informed consent for participation\n* Participants who meet all of the above inclusion criteria\n\nExclusion Criteria:\n\n* Refusal to provide consent for participation in the study\n* Refusal to undergo the study procedures or assessments\n* Determined by the principal investigator to be unsuitable for participation -Meeting any of the above exclusion criteria -","10 Years",{"count":476,"type":22},30,"1 Day","This exploratory clinical trial aims to investigate the mechanism of sequential muscle contractions during normal swallowing processes, including spoon, straw, and cup feeding, in children aged 2 to under 10 years without swallowing disorders. Surface electromyography (sEMG) will be used to evaluate activation patterns of the orbicularis oris, submental, and hyoid muscles during liquid, semi-solid, and solid intake.\n\nThe study seeks to characterize the timing, duration, amplitude, and coordination of swallowing-related muscle activity in typically developing children. Findings from this study are expected to provide foundational physiological data to inform the development of pediatric-specific neuromuscular electrical stimulation (NMES) protocols for dysphagia treatment.",[480,481,482],"Normal Pediatric Swallowing Physiology","Swallowing Muscle Activation Patterns in Children","Swallowing Function",[484,485,486,487,488,489,490],"Pediatric Swallowing","Swallowing Physiology","Surface Electromyography","Swallowing Muscle Activation","Normative Data","Deglutition","Developmental Physiology","2026-03-02",{"date":493,"type":39},"2026-03-06",{"date":495,"type":22},"2026-03-09",{"date":497,"type":22},"2028-01-31",{"name":45,"class":46},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":507,"minAge":18,"maxAge":140,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":47},"100626418","phase-2-intra-lesional-tumor-boost-for-bulky-cervical-cancer-100626418","NCT07435376","Intra-lesional Tumor Boost for Bulky Cervical Cancer","A Prospective Phase 2 Clinical Trial of Intra-lesional Cervical Tumor Boost for Bulky Cervical Cancer","INTLECTUAL","Inclusion Criteria:\n\n* Patients with histologically confirmed squamous cell carcinoma of the cervix.\n* Patients with bulky primary tumor, defined as a tumor volume ≥ 60 cc OR a maximum diameter ≥ 6 cm.\n* Patients aged 19 to 80 years at the time of diagnosis.\n* Patients with an ECOG performance status of 0 to 2.\n* Patients who have voluntarily agreed to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosis of other malignancies within 5 years prior to enrollment (Exceptions: carcinoma in situ of the breast and thyroid cancer).\n* Patients who are medically unfit for definitive concurrent chemoradiotherapy.\n* Patients who have received prior chemotherapy (neoadjuvant chemotherapy) before radiation therapy.\n* Patients with prior history of radiation therapy to the abdomen or pelvis.\n* Patients unable to provide informed consent due to mental or physical disabilities.","FEMALE",{"count":509,"type":22},17,[85],"The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\n* Does the extra radiation boost effectively reduce the tumor size before the internal radiation (brachytherapy) treatment begins?\n* What medical problems (side effects) do participants have when receiving this treatment?\n\nResearchers will give this intra-lesional boost to all participants during their standard radiation therapy to see if it helps shrink the tumor more than usual.\n\nParticipants will:\n\n* Receive radiation therapy to the pelvis with a targeted boost to the tumor for about 5 to 6 weeks\n* Visit the clinic daily for radiation treatment and regularly for checkups Have an MRI scan during the 4th or 5th week of treatment to measure the tumor size\n* Receive internal radiation therapy (brachytherapy) after finishing the external radiation\n* Visit the clinic for follow-up checkups and tests for up to 2 years",[513,514],"Cervical Cancer","Squamous Cell Carcinoma of Cervix",[516,517,518,519,520,521,522,523],"cervical cancer","bulky cervical cancer","squamous cell carcinoma","intra lesional boost","simultaneous integrated boost","imrt","radiotherapy","tumor volume reduction","2026-02-20",{"date":526,"type":39},"2026-02-27",{"date":528,"type":39},"2025-02-23",{"date":530,"type":22},"2028-11-30",{"name":45,"class":46},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":47},"100625379","snuh-immune-checkpoint-inhibitor-induced-hypothyroidism-recovery-trial-100625379","NCT07421869","SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial","S-CORT","Inclusion Criteria:\n\n* Adults aged 19 years or older.\n* Patients with a history of treatment with immune checkpoint inhibitors (ICIs).\n* Developed hypothyroidism during ICI treatment and initiated levothyroxine after starting ICI therapy.\n* Discontinued ICI therapy prior to study enrollment.\n\nExclusion Criteria:\n\n* Use of levothyroxine or antithyroid medications within 3 months prior to initiating ICI therapy.\n* History of thyroid surgery, radioactive iodine therapy, or neck radiation therapy.\n* Current levothyroxine dose ≥0.1 mg at the time of enrollment.",{"count":540,"type":22},107,[25],"The goal of this study is to find out whether hypothyroidism caused by immune checkpoint inhibitors (ICIs) can recover after stopping the ICIs. The study also aims to identify factors that can help predict which patients will be able to stop taking thyroid hormone replacement.\n\nThe main questions the study will answer are:\n\n* What percentage of patients recover normal thyroid function and can stop levothyroxine after stopping ICIs?\n* What clinical or laboratory factors can predict successful withdrawal of levothyroxine?\n\nParticipants will:\n\n* Be adult cancer patients who developed hypothyroidism during ICI treatment and are currently taking levothyroxine\n* Have already stopped ICI therapy\n* Gradually reduce their levothyroxine dose every 3 months if their thyroid function remains normal\n* Stop levothyroxine if thyroid function remains normal at low doses (≤0.025 mg)\n* Be monitored with thyroid function tests and clinical symptoms at each visit",[544],"Hypothyroidism",[544,546,547,548],"Immune checkpoint inhibitors","Thyroid hormones","Levothyroxine","2026-02-11",{"date":551,"type":39},"2026-02-19",{"date":553,"type":39},"2024-06-12",{"date":555,"type":22},"2029-03-04",{"name":45,"class":46},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":582},"100623537","phase-2-exploratory-evaluation-of-the-digital-therapeutic-device-zenicom-for-subacute-stroke-aphasia-100623537","NCT07397923","Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia","Evaluation of the Safety and Efficacy of the Digital Therapeutic Device Zenicom for Improving Aphasia in Patients With Subacute Stroke and Aphasia (AQ ≥25), a Multicenter, Single-blind, Prospective, Randomized Exploratory Clinical Trial","Inclusion Criteria:\n\n* Aged 19 years or older.\n* Confirmed by a specialist to have aphasia caused by a stroke lesion.\n* First-ever subacute stroke (within 3 months of onset) diagnosed via radiological examination (CT, MRI).\n* Diagnosed with aphasia based on the Speech Assessment (PK-WAB-R).\n* Whose native language is Korean.\n\nExclusion Criteria:\n\n* Have progressive or hemodynamically unstable stroke.\n* Having other neurological diseases suspected to affect language ability.\n* Co-morbid major psychiatric disorders requiring continuous medication (e.g., Major Depressive Disorder, Schizophrenia, Bipolar Disorder, Dementia).\n* Co-morbid major neurogenic diseases other than stroke.\n* Confirmed history of degenerative neuropathy.\n* Current or past substance or alcohol use disorder.\n* Visual impairment (Low vision severity: visual acuity of 0.1-0.3 or lower).\n* Intellectual disability.\n* Illiteracy (unable to read and consent).",{"count":453,"type":22},[85],"Clinical Trial Title A Multicenter, Single-Blind, Prospective, Randomized, Exploratory Clinical Trial to Evaluate the Safety and Efficacy of the Digital Therapeutic Device 'Zenicom' for Improving Aphasia in Patients with Subacute Stroke\n\nClinical Trial Objectives To evaluate the efficacy of the digital therapeutic device Zenicom.\n\nTo evaluate the safety of the digital therapeutic device Zenicom.\n\nClinical Trial Period 6 months from the date of clinical trial plan approval by the Ministry of Food and Drug Safety (MFDS).\n\nTarget Condition Patients with aphasia resulting from stroke lesions.\n\nTarget Sample Size Total of 20 subjects (10 in the experimental group and 10 in the control group).\n\nInvestigational Medical Device Zenicom\n\nClinical Trial Methodology\n\n1. Device Information\n\n   A) Experimental Device: Digital Speech Therapy Application\n\n   Group: Performs conventional speech therapy for 30 minutes daily + additional digital speech therapy program during the 2-week treatment period.\n\n   B) Control Device: Conventional Speech Therapy\n\n   Group: Performs only conventional speech therapy for 30 minutes daily during the 2-week treatment period.\n2. Treatment Duration:\n\n   Total 2 weeks (10 working days; total usage of 600 minutes or more).\n3. Visits:\n\nTotal of 3 visits including outpatient and therapy room visits.\n\nVisit 1 (T-1): Screening\n\nVisit 2 (T0): Baseline and Treatment initiation\n\nVisit 3 (T1): Post-treatment assessment\n\nInclusion and Exclusion Criteria\n\n1. Inclusion Criteria Patients who satisfy all of the following criteria:\n\n   Adults aged 19 years or older.\n\n   Patients confirmed by a specialist to have aphasia caused by a stroke lesion.\n\n   Patients with first-ever subacute stroke (within 3 months of onset) diagnosed via radiological examination (CT, MRI).\n\n   Patients diagnosed with aphasia based on the Speech Assessment (PK-WAB-R).\n\n   Patients whose native language is Korean.\n\n   Patients capable of voluntarily consenting to the study.\n2. Exclusion Criteria Patients meeting any of the following criteria will be excluded:\n\nProgressive or hemodynamically unstable stroke.\n\nPatients with other neurological diseases suspected to affect language ability.\n\nCo-morbid major psychiatric disorders requiring continuous medication (e.g., Major Depressive Disorder, Schizophrenia, Bipolar Disorder, Dementia).\n\nCo-morbid major neurogenic diseases other than stroke.\n\nConfirmed history of degenerative neuropathy.\n\nCurrent or past substance or alcohol use disorder.\n\nVisual impairment (Low vision severity: visual acuity of 0.1-0.3 or lower).\n\nIntellectual disability.\n\nIlliteracy (unable to read and consent).\n\nPatients deemed inappropriate for participation for other reasons.\n\nRefusal to participate in the study.\n\nSuspension and Dropout Criteria\n\n1. Suspension Criteria\n\n   If circumstances observed during the trial make it judged unreasonable to continue the study.\n\n   Occurrence of Serious Adverse Events (SAE).\n2. Dropout Criteria\n\nThe subject requests to stop participation or withdraws consent during the trial.\n\nThe investigator determines that the subject cannot continue the trial due to adverse events (e.g., headache, eye fatigue, nausea, dizziness, etc.).\n\nThe subject arbitrarily takes medication expected to affect the comparative evaluation of the investigational device during the trial.\n\nThe dosage of medication that may affect the comparative evaluation of the investigational device is changed during the trial.\n\nDiscovery of major protocol violations, such as violation of inclusion\u002Fexclusion criteria.\n\nThe subject fails to attend scheduled visits and cannot be contacted.\n\nThe subject fails to perform the digital speech therapy program for a total of 600 minutes or more.\n\nThe investigator determines that the trial should be stopped for other reasons.\n\nEndpoints (Outcome Measures)\n\n1. Primary Efficacy Endpoint\n\n   Change in PK-WAB-R scores between T0 and T1 between groups.\n2. Secondary Efficacy Endpoints\n\nChange in K-BNT scores between T0 and T1 between groups.\n\nChange in K-SAQOL-12 scores between T0 and T1 between groups.\n\nStatistical Analysis Methods To evaluate the change in PK-WAB-R between T0 and T1 between groups, an independent two-sample test will be used. Depending on the distribution of the change, a parametric method (Student's t-test) or a non-parametric method (Mann-Whitney U test) will be selected and applied.\n\nTo evaluate the changes in K-BNT and K-SAQOL-12 between T0 and T1 between groups, an independent two-sample test will be used. Depending on the distribution of the change, a parametric method (Student's t-test) or a non-parametric method (Mann-Whitney U test) will be selected and applied.",[568,457],"Aphasia",[570,571,572,573],"digital therapeutics","aphasia treatment","subacute stroke","korean language","2026-02-07",{"date":576,"type":39},"2026-02-10",{"date":578,"type":39},"2025-12-10",{"date":580,"type":22},"2026-08-31",{"name":45,"class":46},3,{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":590,"enrollmentInfo":591,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":47},"100622225","thyroid-hormone-replacement-after-coronary-artery-bypass-grafting-for-patients-with-subclinical-hypothyroidism-100622225","NCT07380854","Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism","RepleniSH","Eligibility Criteria\n\n* Adults aged 19 to 90 years.\n* Patients scheduled to undergo coronary artery bypass graft (CABG) surgery.\n* Subclinical hypothyroidism (SCH), defined as a normal free thyroxine (free T4) level and a thyroid-stimulating hormone (TSH) level greater than 4 μIU\u002FmL, based on testing performed within 31 days prior to surgery.\n\nExclusion Criteria:\n\n* Patients who underwent repeat or emergency CABG surgery\n* Use of LT4 within the previous 4 weeks\n* Use of antithyroid drug use (propylthiouracil, methimazole, or carbimazole) within the previous 3 months\n* Severe comorbid conditions with a life expectancy of less than 1 year (e.g. advanced malignancy)","90 Years",{"count":592,"type":22},338,[25],"The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG).\n\nThe main questions this study aims to answer are:\n\n• Does levothyroxine reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and new arrhythmias, in SCH patients undergoing CABG? Researchers will compare patients who take levothyroxine with those who do not.\n\nParticipants will:\n\n* Be randomly assigned to either receive levothyroxine or not\n* Start the medication one day before surgery if assigned to the treatment group.\n* Have regular follow-up visits to check thyroid function and cardiovascular events for up to five years after surgery.",[596],"Subclinical Hypothyroidism",[598,599,600,601],"subclinical hypothyroidism","coronary artery bypass grafting","thyroid hormones","levothyroxine","2026-01-24",{"date":604,"type":39},"2026-02-02",{"date":606,"type":39},"2022-02-27",{"date":608,"type":22},"2037-02-26",{"name":45,"class":46},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":617,"targetDuration":4,"studyType":23,"phases":618,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":47},"100616442","exploring-the-effects-of-korean-style-mediterranean-diet-kormed-and-physical-activity-measurement-in-patients-with-mgussmm-a-pilot-study-100616442","NCT07305662","Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS\u002FSMM: A Pilot Study","KORMED-PA Stud","Inclusion Criteria:\n\nParticipants must meet all of the following:\n\nAdults aged 19 to 80 years at the time of enrollment.\n\nDiagnosed with MGUS (Monoclonal Gammopathy of Undetermined Significance) or Smoldering Multiple Myeloma (SMM) according to standard criteria.\n\nAble and willing to follow a Korean-style Mediterranean diet (KORMED) for 12 weeks.\n\nAble to use a smartphone and wearable device to track daily physical activity.\n\nWilling to attend study visits and provide blood, stool, and questionnaire data at scheduled time points.\n\nAble to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Participants will not be eligible if they meet any of the following:\n\nDiagnosis of active multiple myeloma requiring treatment.\n\nCurrent participation in another interventional clinical trial.\n\nSevere liver, kidney, or heart disease that would make the diet or study procedures unsafe.\n\nUncontrolled infection or serious medical condition that may interfere with participation.\n\nHistory of major gastrointestinal surgery that prevents adherence to the diet.\n\nPregnant or breastfeeding, or planning to become pregnant during the study period.\n\nAllergy or intolerance to key components of the KORMED diet (e.g., fish, nuts, legumes) that prevents safe participation.\n\nAny condition, in the investigator's judgment, that would make participation unsafe or limit the ability to complete the study.",{"count":453,"type":22},[25],"This single-arm pilot study aims to evaluate the feasibility and potential health effects of a Korean-style Mediterranean diet (KORMED) and continuous physical activity measurement in patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). The study investigates whether a 12-week KORMED dietary intervention, combined with monitoring of daily step counts using a wearable device, can improve metabolic and inflammatory biomarkers, body composition, gut microbiome diversity, and quality of life.\n\nThe study seeks to answer the following primary question:\n\nIs the KORMED diet feasible and achievable for MGUS\u002FSMM patients, as measured by changes in K-MEDAS adherence scores over 12 weeks?\n\nSecondary questions include:\n\n1. Does adherence to KORMED lead to improvements in BMI, inflammatory markers (CRP, IL-6), metabolic indicators (HOMA-IR, FLI), M-protein levels, and gut microbiome diversity?\n2. Is increased daily physical activity, measured by step counts, associated with favorable changes in metabolic and clinical parameters?\n3. Can combined dietary and activity-based lifestyle modification provide preliminary evidence supporting delayed disease progression in precursor plasma cell disorders?",[621,622],"Monoclonal Gammopathy of Undetermined Significance","Smoldering Myeloma","2026-01-20",{"date":625,"type":39},"2026-01-21",{"date":627,"type":22},"2026-01-30",{"date":629,"type":22},"2027-07-15",{"name":45,"class":46},""]